Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney

NCT ID NCT03816332

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplanted kidney. About 12 participants with advanced melanoma, Merkel cell, or other skin cancers that cannot be surgically removed are being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma cutaneous melanoma cutaneous neuroendocrine carcinoma Lynch syndrome melanoma metastatic melanoma metastatic squamous cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 CLINICAL STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 CLINICAL STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 METASTATIC BASAL CELL CARCINOMA METASTATIC MELANOMA METASTATIC MERKEL CELL CARCINOMA METASTATIC SKIN SQUAMOUS CELL CARCINOMA PATHOLOGIC STAGE III CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIA CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIIB CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 PATHOLOGIC STAGE IIIC CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IIID CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8 PATHOLOGIC STAGE IV CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 UNRESECTABLE BASAL CELL CARCINOMA UNRESECTABLE MELANOMA UNRESECTABLE MERKEL CELL CARCINOMA

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida, 33612, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.